Zobrazeno 1 - 10 of 33 pro vyhledávání: '"S. Cheporov"'
1
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
Autor: P. Bhar, D. Krasnojon, Georgiy M. Manikhas, John R. McGuire, William J. Gradishar, A. Makhson, Jose Iglesias, S. Cheporov, Alicia Clawson
Publikováno v: Clinical Breast Cancer. 12:313-321
Background A randomized phase II study in first-line MBC demonstrated superior efficacy and safety of weekly nab -paclitaxel compared with docetaxel. Final survival analyses and updated safety results are reported. Patients and Methods Three hundred
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8f4fa70c51c0e23b69cc76ae809865
https://doi.org/10.1016/j.clbc.2012.05.001
Zobrazit plný text záznamu
2
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
Autor: D. W. Miles, Vladimir Semiglazov, Binghe Xu, L. Goedhals, Aman U. Buzdar, Karen Rittweger, S. Tjulandin, S. Hoersch, Joyce O'Shaughnessy, R. Digumarti, E. Gotovkin, X. Hu, S. Cheporov
Publikováno v: Annals of Oncology. 23:589-597
This phase II study investigated whether a lower-than-approved dose of capecitabine, plus docetaxel (XT), would improve tolerability versus standard-dose XT without compromising efficacy.Women aged ≥18 years with locally advanced/metastatic breast
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69c0c0d88da6f35d354e8f90a690b9c
https://doi.org/10.1093/annonc/mdr256
Zobrazit plný text záznamu
3
P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2
Autor: P. Bhar, D. Krasnojon, Georgy M. Manikhas, Alicia Clawson, S. Cheporov, William J. Gradishar, A. Makhson
Publikováno v: Cancer Research. 71:P5-19
Background We previously reported the results of a phase II study evaluating the efficacy and safety of 3 different dosing regimens of ab-pac and docetaxel for the first-line treatment of MBC (Gradishar et al. J ClinOncol. 2009;27:3611). Here we repo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5e70a04772de960f357a13288021a3b
https://doi.org/10.1158/0008-5472.sabcs11-p5-19-13
Zobrazit plný text záznamu
4
P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial
Autor: A. Makhson, S. Cheporov, P. Bhar, D. Krasnojon, Alicia Clawson, Georgy M. Manikhas, William J. Gradishar
Publikováno v: Cancer Research. 71:P5-19
Background We previously reported the results of a phase II study evaluating the efficacy and safety of 3 different dosing regimens of ab-pac and docetaxel for the first-line treatment (Tx) of MBC (Gradishar et al. J Clin Oncol. 2009;27:3611–3619).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b0271dff0cb36a2fab26896d2ec87ef
https://doi.org/10.1158/0008-5472.sabcs11-p5-19-03
Zobrazit plný text záznamu
5
Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC)
Autor: R. Digumarti, Aman U. Buzdar, F. Schaedeli Stark, S. Cheporov, F Gilberg, Sergei Tjulandin, L. Goedhals, E. Gotovkin, Vladimir Semiglazov, K Rittweger, Binghe Xu, X. Hu
Publikováno v: Cancer Research. 70:P6-11
Background: In the phase III registration trial of capecitabine (X) plus docetaxel (T) in MBC (SO14999), a higher proportion of pts treated with XT vs T alone experienced grade 3/4 AEs (78% vs 64%, respectively), and dose reductions (65% vs 36%, resp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35fc0371137f71b97a911a96816b15a6
https://doi.org/10.1158/0008-5472.sabcs10-p6-11-02
Zobrazit plný text záznamu
6
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Autor: Georgiy M. Manikhas, A. Makhson, Daniil L. Stroyakovsky, Petr K. Yablonsky, P. Bhar, Sergei V. Orlov, S. Cheporov, Jose Iglesias, Mark A. Socinski
Publikováno v: Journal of Thoracic Oncology. 5:852-861
Introduction This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab -paclitaxel plus q3w carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) for a phase 3 trial. Met
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a320c1b53f5385f29badb1b76f9309c
https://doi.org/10.1097/jto.0b013e3181d5e39e
Zobrazit plný text záznamu
7
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
Autor: P. Bhar, Georgiy M. Manikhas, William J. Gradishar, Alicia Clawson, D. Krasnojon, S. Cheporov, A. Makhson
Publikováno v: Journal of Clinical Oncology. 27:3611-3619
Purpose In patients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor activity compared with patients who received solvent-based paclitaxel. This phase II study examined the antitumor activity and safety of w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc47da1fdba36b1c7ec2f979def71480
https://doi.org/10.1200/jco.2008.18.5397
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje